Bombay HC upholds compulsory license granted to Natco Pharma on Nexavar

16 Jul 2014 Evaluate

The Bombay High Court has upheld the compulsory license (CL) granted Natco Pharma on Nexavar (sorafenib tosylate) of German drug major Bayer’s patented kidney cancer drug.

The Nexavar issue dates back to March 9, 2012, when the then Controller General of Patents issued the first-ever CL to the company to manufacture an affordable generic version of sorafenib tosylate, the anti-cancer drug for which Bayer had obtained a patent.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

895.90 -12.20 (-1.34%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×